<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299880</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-901</org_study_id>
    <secondary_id>2019-004753-87</secondary_id>
    <nct_id>NCT04299880</nct_id>
  </id_info>
  <brief_title>Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols</brief_title>
  <official_title>A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, multi-national, non-randomized rollover study designed&#xD;
      to allow continued access to napabucasin for patients who have participated in a Boston&#xD;
      Biomedical-sponsored study and are being treated with napabucasin (monotherapy or&#xD;
      combination) and who are deriving continued clinical benefit in the parent study at the time&#xD;
      of closure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, multi-national, non-randomized rollover study designed&#xD;
      to allow continued access to napabucasin for patients who have participated in a Boston&#xD;
      Biomedical-sponsored study and are being treated with napabucasin (monotherapy or&#xD;
      combination) and who are deriving continued clinical benefit in the parent study at the time&#xD;
      of closure. Individual patients will continue to be treated with napabucasin (monotherapy or&#xD;
      combination) in accordance with the parent study under which they were enrolled. If the dose&#xD;
      was reduced in the parent protocol, the dose of the last visit of the parent study will be&#xD;
      used. Patients will be monitored to determine long term safety and tolerability of&#xD;
      napabucasin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Individual patients will continue to be treated with napabucasin (monotherapy or combination) in accordance with the parent study under which they were enrolled.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From first dose until 30 days following last dose of napabucasin</time_frame>
    <description>Adverse Events, including clinically significant laboratory abnormalities, as characterized by type, frequency, severity (as graded by NCI CTCAE version 4.0), seriousness, and relationship to study therapy.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Napabucasin monotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive napabucasin administered orally, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Napabucasin in combination with Gemcitabine and Nab-paclitaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Napabucasin in combination with Nivolumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Napabucasin in combination with paclitaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Napabucasin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
    <arm_group_label>Napabucasin in combination with Gemcitabine and Nab-paclitaxel</arm_group_label>
    <arm_group_label>Napabucasin in combination with Nivolumab</arm_group_label>
    <arm_group_label>Napabucasin in combination with paclitaxel</arm_group_label>
    <arm_group_label>Napabucasin monotherapy</arm_group_label>
    <other_name>BBI608</other_name>
    <other_name>BBI-608</other_name>
    <other_name>BB608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with Gemcitabine and Nab-paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with Gemcitabine and Nab-paclitaxel</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Napabucasin in combination with FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. The patient is currently participating in a BBI-sponsored parent study of napabucasin&#xD;
             and must be receiving napabucasin as monotherapy or as part of a combination&#xD;
             treatment.&#xD;
&#xD;
          2. Written, signed consent for trial participation must be obtained from the patient&#xD;
             appropriately in accordance with applicable International Conference on Harmonisation&#xD;
             (ICH) guidelines and local and regulatory requirements prior to the performance of any&#xD;
             study specific procedure.&#xD;
&#xD;
          3. Must be â‰¥18 years of age.&#xD;
&#xD;
          4. Currently has no evidence of progressive disease, as determined by the investigator,&#xD;
             during treatment with napabucasin (either as monotherapy or as part of a combination&#xD;
             treatment regimen) or are deriving clinical benefit despite disease progression&#xD;
             according to Investigator's clinical judgement.&#xD;
&#xD;
          5. Continued ability to swallow and retain orally administered study drug(s) and does not&#xD;
             have any clinically significant GI abnormalities that may alter absorption such as&#xD;
             malabsorption syndrome.&#xD;
&#xD;
          6. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test at screening.&#xD;
&#xD;
          7. Non-fertile or agree to use an adequate method of contraception while on study and for&#xD;
             6 months following the last dose and not currently nursing; males agree to use an&#xD;
             adequate method of contraception while on study and for 3 months following the last&#xD;
             dose (Appendix 3).&#xD;
&#xD;
          8. Patients must be accessible for treatment and follow-up. Patients registered on this&#xD;
             trial must receive protocol treatment and be followed at their current (parent study)&#xD;
             participating center.&#xD;
&#xD;
          9. Patient agrees not to participate in other interventional clinical studies during&#xD;
             their participation in this trial. Patients participating in surveys or observational&#xD;
             studies are eligible to participate in this study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Permanent discontinuation of napabucasin in the parent study.&#xD;
&#xD;
          2. Napabucasin dose interruption for &gt;4 weeks between the last dose on the parent study&#xD;
             and first dose on the rollover study.&#xD;
&#xD;
          3. Women who are pregnant or breastfeeding. Women should not breastfeed while taking&#xD;
             study treatment and for 4 weeks after the last dose of napabucasin. Women undergoing&#xD;
             combination backbone therapy should not breast feed while on combination backbone&#xD;
             therapy and for the period of time following discontinuation of combination backbone&#xD;
             therapy as specified in the parent protocol.&#xD;
&#xD;
          4. Hypersensitivity to napabucasin or one of the excipients.&#xD;
&#xD;
          5. Any active disease condition which would render the protocol treatment dangerous or&#xD;
             impair the ability of the patient to receive protocol therapy.&#xD;
&#xD;
          6. Any condition (e.g. psychological, geographical, etc.) that does not permit compliance&#xD;
             with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Digestive System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

